Bone Biologics (BBLG) Cash from Financing Activities (2013 - 2025)
Bone Biologics (BBLG) posted quarterly Cash from Financing Activities of $4.4 million for Q2 2025, up 1455683.28% year-over-year from N/an in Q2 2024, and up 1152.43% quarter-over-quarter from $347549.0 in Q1 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Cash from Financing Activities for 12 consecutive years, with $4.4 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Cash from Financing Activities rose 1455683.28% year-over-year to $4.4 million; the TTM figure through Dec 2025 stood at $4.7 million (up 6.26% YoY), while the FY2025 annual figure was $4.7 million, up 6.26% from the prior year.
- Cash from Financing Activities improved to $4.4 million in Q2 2025 per BBLG's latest filing, from $347549.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $6.9 million in Q4 2021 and bottomed at $299.0 in Q2 2024.
- Historically, Cash from Financing Activities has averaged $1.6 million across 4 years, with a median of $591998.0 in 2023.
- On a YoY basis, Cash from Financing Activities climbed as much as 1455683.28% in 2025 and fell as far as 76.9% in 2025.
- Bone Biologics' Cash from Financing Activities stood at $6.9 million in 2021, then plunged by 91.37% to $591998.0 in 2023, then surged by 87.87% to $1.1 million in 2024, then jumped by 291.37% to $4.4 million in 2025.
- Business Quant data shows BBLG's Cash from Financing Activities at $4.4 million in Q2 2025, $347549.0 in Q1 2025, and $1.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 347,549.00 |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 299.00 |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 591,998.00 |
| Dec 31, 2021 | 6.86 Mn |
| Sep 30, 2021 | 276,706.00 |
| Jun 30, 2021 | 569,254.00 |
| Mar 31, 2021 | 199,148.00 |
| Dec 31, 2020 | 123,232.00 |
| Sep 30, 2020 | 74,689.00 |
| Jun 30, 2020 | 76,702.00 |
| Mar 31, 2020 | 128,165.00 |
| Dec 31, 2019 | 120,000.00 |
| Sep 30, 2019 | 500,000.00 |
| Jun 30, 2019 | 1.00 Mn |
| Mar 31, 2019 | 700,000.00 |
| Sep 30, 2018 | 3.27 Mn |